

Review

Not peer-reviewed version

Artificial Intelligence and Oral Cancer Diagnosis: Current Evidence, Critical Limitations, and the Basic Science Priorities Essential for Improving Diagnostic Accuracy

[Boluwatife Olu Afolabi](#)* and Torojah M Williams

Posted Date: 28 February 2026

doi: 10.20944/preprints202602.1934.v1

Keywords: oral cancer; oral squamous cell carcinoma; artificial intelligence; deep learning; diagnostic imaging; histopathology; multiomics; tumor microenvironment



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Review

Artificial Intelligence and Oral Cancer Diagnosis: Current Evidence, Critical Limitations, and the Basic Science Priorities Essential for Improving Diagnostic Accuracy

Boluwatife Olu Afolabi ^{1,*} and Torojah M Williams ²

¹ University of Minnesota School of Dentistry, Department of Diagnostic and Biological Sciences;

² Medical College of Wisconsin, Institute for Health and Humanity

* Correspondence: afola023@umn.edu

Abstract

Oral cancer remains one of the deadliest malignancies with more than half of late-stage patients dying within five years of diagnosis globally. Late presentation before initial diagnosis is a principal driver of poor outcomes for the disease. Artificial intelligence (AI), particularly deep learning systems, has emerged as a promising tool to improve the sensitivity and timeliness of oral cancer detection. This narrative review examines the current state of AI-assisted oral cancer diagnosis, evaluating the performance of image-based approaches [including convolutional neural networks (CNNs) applied to clinical photographs, histopathological slides, and cytology workflows] and critically analyzes where these systems fall short. Of note is the fact that AI models are functionally blind to submucosal and early infiltrating lesions without visible surface change, and their detection of high-grade epithelial dysplasia remains poor. Model generalizability across institutions is further compromised by the absence of large-scale standardized oral cancer image repositories. This review argues that the next frontier must shift from morphology-based learning to biologically informed AI [specifically through multiomics integration, tumor microenvironment characterization, and molecular imaging biomarkers] in order to detect oral cancer earlier and more reliably.

Keywords: oral cancer; oral squamous cell carcinoma; artificial intelligence; deep learning; diagnostic imaging; histopathology; multiomics; tumor microenvironment

Introduction

Oral squamous cell carcinoma (OSCC) accounts for the overwhelming majority of oral cavity malignancies and continues to carry one of the highest mortality rates among cancers for which established screening pathways exist ¹. The five-year survival rate for oral cancer in low and middle-income countries (LMIC) remains approximately 25-45% ^{2,3}, a figure that has not improved meaningfully over several decades despite significant advances in surgical, radiation, and systemic oncology ⁴. The primary driver of this persistent mortality burden is the disproportionately high rate of late-stage [III-IV] diagnosis ⁵. When oral cancers are detected at Stage I or II, five-year survival rates exceed 70–80%; unfortunately, this figure drops dramatically with advanced-stage disease ⁶.

Some of the barriers to early detection are embedded in our current diagnostic standards. Conventional clinical visual examination [which is the the predominant screening method in most healthcare settings] has a pooled sensitivity of approximately 70% ⁷, for detecting dysplastic and malignant oral lesions, meaning that a substantial proportion of early lesions are still missed even by trained clinicians. Oral potentially malignant disorders (OPMDs) such as leukoplakia and erythroplakia represent important targets for secondary prevention, but their clinical heterogeneity

and the inter-examiner variability inherent to conventional visual assessment create a well-documented diagnostic gap that the current standard of care cannot consistently close ⁸.

Artificial intelligence offers a credible and increasingly well-supported pathway to addressing these gaps. Machine learning approaches [particularly deep learning architectures] have demonstrated meaningful performance advantages over conventional diagnostic techniques across multiple oncologic applications ⁹. In the oral cancer space, the pace of research has accelerated considerably over the past decade, with multiple meta-analyses now available characterizing the aggregate performance of AI systems in oral cancer detection ^{10,11}. However, translation of promising research outputs into generalizable clinical tools has been inconsistent ¹², and a clear-eyed analysis of where the technology works, where it does not, and what basic science focus should be prioritized is necessary to guide both research investment and implementation strategy.

This narrative review synthesizes current evidence on AI-assisted oral cancer diagnosis, offers a structured critique of the field's principal limitations, and proposes a forward-looking framework for the biological and computational advances required to meaningfully improve oral cancer outcomes.

Literature Search Strategy

This narrative review synthesizes peer-reviewed literature on artificial intelligence applications in oral cancer diagnosis. Relevant publications were identified through searches of PubMed, Scopus, and Google Scholar using combinations of keywords including "oral cancer," "oral squamous cell carcinoma," "artificial intelligence," "deep learning," and "machine learning." Studies were selected based on relevance to diagnostic performance, biological limitations, and translational clinical applicability.

Current Landscape of AI-Assisted Oral Cancer Detection

In the oral cancer domain, the predominant AI-assisted diagnostic strategy is image-based deep learning; of which the most common is convolutional neural networks trained on clinical photographs, histopathological whole-slide images, and oral endoscopic images ¹³. CNNs are a class of artificial neural networks well-suited to visual pattern recognition due to their ability to learn hierarchical spatial features from raw pixel data through successive convolutional layers ¹⁴. These models have been trained across a range of input types, from standardized photographic archives to whole-slide images digitized from biopsy specimens.

Published meta-analyses show that AI-based, predominantly CNN-driven oral cancer detection systems achieve pooled sensitivities around 87–90% and specificities around 81–90% ^{9,15}. One meta-analysis of mixed AI models for oral cancer and OPMDs reported a pooled sensitivity of 0.87, specificity of 0.81, and a diagnostic odds ratio (DOR) of 131.6, while a CNN-focused meta-analysis in oral squamous cell carcinoma found a DOR exceeding 260 with an area under curve (AUC) of 0.98 ¹⁶. This performance profile represents a clinically meaningful advantage over unaided conventional oral examination, which shows a pooled sensitivity of about 70% for detecting dysplastic and malignant oral lesions and is highly operator dependent ⁷. Additionally, emerging comparative data indicate that deep learning models now often outperform earlier machine learning classifiers [including logistic regression and support vector machines] on many published oral cancer detection benchmarks, particularly for image-based tasks ¹⁰. Hybrid approaches combining CNN-based feature extraction with ensemble classifiers have pushed accuracy above 95% on some OSCC datasets ¹⁷.

Beyond static image classification, AI-assisted endoscopy has begun to exploit advanced segmentation architectures [such as U-Net and related deep semantic segmentation models] to differentiate intraoral tissue types in endoscopic hyperspectral imaging, achieving high F1-scores [around 0.84–0.86] across multiple tissue classes in *in vivo* settings ¹⁸. AI-integrated cytology workflows are also increasingly being evaluated alongside conventional histopathology as a complementary diagnostic modality ¹⁹.

High-Performing Applications

CNNs applied to digitized histopathological slides represent the highest-performing application currently available in the AI oral cancer literature ²⁰. These models excel because histopathology provides standardized, high-resolution input in a training environment where deep learning architectures are naturally suited to exploit subtle morphological differences in cellular architecture, nuclear pleomorphism, and tissue organization ^{21,22}. The performance characteristics of histopathology-based AI are broadly reproducible across datasets and represent the most mature area of the field.

Clinical image analysis has also matured considerably. Systems trained on OPMDs, particularly leukoplakia, perform with high consistency, and smartphone-integrated AI platforms have demonstrated near-expert-level diagnostic accuracy in community screening settings ²³. This is a particularly meaningful development for resource-limited environments, where limited specialist access and high rates of late-stage presentation converge to create the greatest unmet diagnostic need. Custom-designed CNN architectures built specifically for oral cancer [rather than adapted from general image classifiers] have reported precision above 91%, sensitivity of 94%, and categorization accuracy of 95% for oral tumors, suggesting that disease-specific model design confers meaningful performance advantages over repurposed general architectures ²⁰.

Table 1. AI Performance Benchmarks in Clinical Imaging.

Metric	Repurposed General AI (e.g., VGG/ResNet)	Custom Oral Cancer CNNs
Categorization Accuracy	85.0% – 88.4% ²⁰	95.2% ²⁰
Sensitivity	84.1% – 87.0% ²⁰	94.5% ²⁰
Precision	86.0% – 89.2% ²⁰	91.1% ²⁰
Global Applicability	Limited by demographic bias ²⁴	High potential for LMIC screening ²³

Critical Limitations of Current AI Approaches

A key limitation of many current AI oral-cancer detection systems [particularly those based on clinical photographs or white-light imaging] is that they primarily model surface-visible features and therefore may not reliably identify pathology whose most salient signal is submucosal ²⁵. This is clinically important because depth of invasion is incorporated into the American Joint Committee on Cancer staging system (AJCC) 8 staging and is an important predictor of nodal metastasis and adverse outcomes, including extracapsular spread ²⁶.

Detection of high-grade epithelial dysplasia, which is arguably the highest-value target for secondary prevention, also underperforms in current AI workflows ²⁷. One AI-integrated cytology platform reported sensitivity of only 18% for high-grade dysplasia, a figure comparable to conventional cytology alone and insufficient for meaningful clinical utility ²⁸. The major biological explanation for this failure is that cells exfoliated from deeper epithelial layers in highly keratinized squamous mucosa are both difficult to sample adequately and morphologically ambiguous, creating noise in training data that confounds even well-optimized classifiers ²⁹.

General-purpose large language model-based image recognition tools have also been evaluated with some sobering results. GPT-4-based image recognition performed inconsistently on OSCC

images when clinical history was not provided as context, making it unreliable for clinical decision-support in its current form ²⁴. Across the broader field, model generalizability across institutions remains a structural problem due to majority of published AI systems being trained and validated on single-center datasets, which constrains external reproducibility and limits the evidence base for multi-site deployment ³⁰. The absence of large-scale, standardized, and annotated oral cancer image repositories compounds this, functioning as a structural bottleneck that limits both the diversity of training data and the rigor of benchmarking ²³.

Table 2. Comparative Diagnostic Utility and Primary Limitations.

Modality	HGD Sensitivity	Primary Limitation
Conventional Cytology	~18% – 25%	Sampling depth; manual observer fatigue; keratinization. ²⁸
AI-Integrated Cytology	~18% (in specific platforms)	Reliance on surface morphology; inability to access deeper tissue layers. ²⁷
Histopathology (Gold Standard)	~90% – 100%	Invasive; captures full-thickness architecture. ³¹

Basic Science Priorities for Next-Generation Ai Oral Cancer Tools

As we have stated earlier, the fundamental constraint on current AI performance is that these systems learn from morphology alone ³¹. However, oral carcinogenesis [like any other tissue-specific cancer] is driven by molecular events such as transcriptional reprogramming, epigenetic dysregulation, and immune microenvironment remodeling that precede visible tissue change by months to years ³²⁻³⁴. For AI to detect oral cancer earlier and more reliably, the field must transition toward training models on biologically meaningful molecular signals.

Three scientific urgencies are clear and should be prioritized in order to make the leap towards the next generation of diagnostic AI products in oral carcinogenesis. First, multiomics integration. Machine learning models that incorporate transcriptomic, proteomic, and epigenomic data consistently outperform image-only models on cancer classification tasks ³⁵. Convergent biological processes involved in oral carcinogenesis; like metabolic reprogramming, immune-inflammatory remodeling, microbiome dysbiosis, and epithelial-stromal disruption, are now identifiable as molecular signatures that precede histologic transformation ³⁶. AI models trained to recognize these molecular patterns could substantially compress the diagnostic window and identify malignant progression before a visual phenotype emerges ³⁷.

Second, tumor microenvironment (TME) characterization. Advances in spatial transcriptomics and single-cell RNA sequencing now enable characterization of the OSCC cellular architecture at resolutions previously unavailable ²². AI models encoding TME features [including immune cell composition, cancer-associated fibroblast activation states, and extracellular matrix remodeling signatures] can capture information directly relevant to invasion risk and immune evasion ³⁸, dimensions that image-based AI is structurally incapable of accessing ³⁹.

Third, molecular imaging biomarkers. TME-targeted molecular imaging enables detection of functional tissue changes before structural alterations become visible on standard clinical or radiological examination ⁴⁰. Integrating these signals into AI training pipelines represents a direct strategy for addressing the submucosal blind spot and could extend the clinical detection window into the preclinical invasive phase of oral carcinogenesis.

Table 3. Comparison of Diagnostic Modalities in AI Development.

Feature	Surface Image-Based AI	Multi-Omics & TME-Informed AI
Primary Input	Morphology (RGB/Optical) ²⁰	Transcriptomics, Proteomics, Spatial data ³⁷
Detection Timing	Visible phenotype (Stage I-IV) ²³	Pre-clinical molecular shifts ⁴⁰
Biological Depth	Surface-level only ²⁵	Submucosal & cellular architecture ²²
Key Limitation	Submucosal blind spot ²⁵	High cost and data complexity ¹²

Conclusions

Artificial intelligence has demonstrated meaningful diagnostic performance in oral cancer detection, particularly in histopathological slide analysis and clinical image-based classification of OPMDs, and the performance advantage relative to unaided clinical examination is now well-established and clinically significant. However, the current generation of AI tools operates within a narrow morphological paradigm that cannot detect the molecular events driving early invasion, cannot reliably identify high-grade dysplasia, and lacks the cross-institutional generalizability required for broad clinical deployment. Addressing these gaps requires coordinated progress in basic cancer biology, multiomics methodology, spatial transcriptomics, and molecular imaging. The extent to which the field advances on these fronts in the coming years will determine whether AI can genuinely change oral cancer survival outcomes or not.

Author Contributions: Conceptualization: Boluwatife Olu Afolabi Literature review and evidence synthesis: Boluwatife Olu Afolabi, Torojah M Williams Writing – original draft preparation: Boluwatife Olu Afolabi Writing – review and editing: Boluwatife Olu Afolabi, Torojah M Williams All authors have read and approved the final manuscript.

Funding: This research received no external funding.

Ethics Approval and Consent to Participate: This article is a narrative review of previously published literature and does not involve new human participants, patient data, or animal subjects. Therefore, ethical approval and informed consent were not required.

Consent for Publication: Not applicable.

Data Availability Statement: No new data were generated or analyzed in this study.

Conflicts of Interest: The authors declare no competing interests.

References

1. Bray, F. *et al.* Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* **n/a**.
2. Francis, D. L. & Pape Reddy, S. S. Oral Cancer Disparities in Low- and Middle-Income Countries: A Global Health Equity Perspective on Prevention, Early Detection, and Treatment Access. *Ann. Glob. Health* **91**, 81 (2025).
3. Adegbesan, A. *et al.* Cancer navigation in Africa: challenges, impacts, and future directions. *Support. Care Cancer* **34**, 205 (2026).
4. Pannunzio, S. *et al.* Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives. *Front. Oncol.* **13**, (2024).

5. Su, W. W.-Y. *et al.* Impact of treatment delay on survival of oral/oropharyngeal cancers: Results of a nationwide screening program. *Head Neck* **43**, 473–484 (2021).
6. González-Moles, M. Á., Aguilar-Ruiz, M. & Ramos-García, P. Challenges in the Early Diagnosis of Oral Cancer, Evidence Gaps and Strategies for Improvement: A Scoping Review of Systematic Reviews. *Cancers* **14**, 4967 (2022).
7. Essat, M. *et al.* Diagnostic accuracy of conventional oral examination for detecting oral cavity cancer and potentially malignant disorders in patients with clinically evident oral lesions: Systematic review and meta-analysis. *Head Neck* **44**, 998–1013 (2022).
8. van der Waal, I. Oral potentially malignant disorders: Is malignant transformation predictable and preventable? *Med. Oral Patol. Oral Cir. Bucal* **19**, e386–e390 (2014).
9. Sahoo, R. K. *et al.* Diagnostic performance of artificial intelligence in detecting oral potentially malignant disorders and oral cancer using medical diagnostic imaging: a systematic review and meta-analysis. *Front. Oral Health* **5**, (2024).
10. Liu, P. & Bagi, K. A tailored deep learning approach for early detection of oral cancer using a 19-layer CNN on clinical lip and tongue images. *Sci. Rep.* **15**, 23851 (2025).
11. Sufiawati, I., Insyafiana, A., Rahman, R. & Idris, A. A bibliometric analysis reveals a dynamic growth in the use of artificial intelligence in oral cancer research over three decades. *Discov. Oncol.* **16**, 1432 (2025).
12. Xu, Y., Li, Y., Wang, F., Zhang, Y. & Huang, D. Addressing the current challenges in the clinical application of AI-based Radiomics for cancer imaging. *Front. Med.* **12**, 1674397 (2025).
13. Heo, J. *et al.* Deep learning model for tongue cancer diagnosis using endoscopic images. *Sci. Rep.* **12**, 6281 (2022).
14. Benil, T. *et al.* Detect pre-cancerous tongue lesions for early oral cancer diagnosis using deep learning algorithm. *Sci. Rep.* **15**, 41828 (2025).
15. Li, J. *et al.* Diagnostic accuracy of artificial intelligence assisted clinical imaging in the detection of oral potentially malignant disorders and oral cancer: a systematic review and meta-analysis. *Int. J. Surg. Lond. Engl.* **110**, 5034–5046 (2024).
16. Shen, M. *et al.* Diagnostic performance of convolutional neural network-based AI in detecting oral squamous cell carcinoma: a meta-analysis. *BMC Oral Health* <https://doi.org/10.1186/s12903-025-07543-5> (2026) doi:10.1186/s12903-025-07543-5.
17. El-Aziz, A. A. A., Mahmood, M. A. & El-Ghany, S. A. Enhancing Early Detection of Oral Squamous Cell Carcinoma: A Deep Learning Approach with LRT-Enhanced EfficientNet-B3 for Accurate and Efficient Histopathological Diagnosis. *Diagnostics* **15**, 1678 (2025).
18. Römer, P. *et al.* Enhancing Oral Health Diagnostics With Hyperspectral Imaging and Computer Vision: Clinical Dataset Study. *JMIR Med. Inform.* **13**, e76148 (2025).
19. Tayebi-Hillali, H. *et al.* Accuracy of Cytological Methods in Early Detection of Oral Squamous Cell Carcinoma and Potentially Malignant Disorders: A Systematic Review and Meta-Analysis. *J. Oral Pathol. Med.* **54**, 507–527 (2025).
20. Ramani, R. S. *et al.* Convolutional neural networks for accurate real-time diagnosis of oral epithelial dysplasia and oral squamous cell carcinoma using high-resolution in vivo confocal microscopy. *Sci. Rep.* **15**, 2555 (2025).
21. Shephard, A. J. *et al.* A fully automated and explainable algorithm for predicting malignant transformation in oral epithelial dysplasia. *NPJ Precis. Oncol.* **8**, 137 (2024).
22. Liu-Swetz, Y. *et al.* AI-driven prediction of progression to oral squamous cell carcinoma using a multiresolution pathology model. *Npj Digit. Med.* **8**, 657 (2025).
23. Zhang, Y.-L., Zhang, X.-K. & Fu, T.-G. Artificial intelligence reshapes early oral cancer screening: from image recognition to risk prediction. *Int. J. Surg. Lond. Engl.* **111**, 9874–9875 (2025).
24. Karuppan Perumal, M. K., Rajan Renuka, R., Kumar Subbiah, S. & Manickam Natarajan, P. Artificial intelligence-driven clinical decision support systems for early detection and precision therapy in oral cancer: a mini review. *Front. Oral Health* **6**, (2025).
25. Talwar, V. *et al.* AI-Assisted Screening of Oral Potentially Malignant Disorders Using Smartphone-Based Photographic Images. *Cancers* **15**, 4120 (2023).

26. AJCC 8th Edition Staging of Oral Cavity Cancer: Radiologic Evaluation. *J. Korean Soc. Radiol.* **87**, 3–11 (2026).
27. Xu, Z., Lin, A. & Han, X. Current AI Applications and Challenges in Oral Pathology. *Oral* **5**, 2 (2025).
28. Sunny, S. *et al.* A smart tele-cytology point-of-care platform for oral cancer screening. *PLoS ONE* **14**, e0224885 (2019).
29. Kokubun, K., Nakajima, K., Yamamoto, K., Akashi, Y. & Matsuzaka, K. Evaluation of oral brush liquid-based cytology for oral squamous cell carcinoma: a comparative study of cytological and histological diagnoses at a single center. *BMC Oral Health* **23**, 145 (2023).
30. Araújo, A. L. D., Pedroso, C. M., Vargas, P. A., Lopes, M. A. & Santos-Silva, A. R. Advancing oral cancer diagnosis and risk assessment with artificial intelligence: a review. *Explor. Digit. Health Technol.* **3**, 101147 (2025).
31. Andrzejczak, B. *et al.* Use of Artificial Intelligence for Diagnosing Oral Mucosa Conditions: A Review. *Diagnostics* **16**, 365 (2026).
32. Hanahan, D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* **12**, 31–46 (2022).
33. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. *Cell* **144**, 646–674 (2011).
34. Bashir, M. K., Afolabi, B. & Opeodu, O. I. Chronic periodontitis: A risk for oral cancer. *Dentoscope* **23**, 41–45 (2017).
35. Kang, Y. J., Lee, Y. G., Chung, M. J., Kim, J. & Choi, N. Deep learning-based artificial intelligence models predict survival in patients with oral cavity squamous cell carcinoma. *Sci. Rep.* **15**, 43537 (2025).
36. Alsahafi, E. *et al.* Clinical update on head and neck cancer: molecular biology and ongoing challenges. *Cell Death Dis.* **10**, 1–17 (2019).
37. Wang, J. M. *et al.* Deep learning integrates histopathology and proteogenomics at a pan-cancer level. *Cell Rep. Med.* **4**, (2023).
38. Shephard, A. J., Mahmood, H., Raza, S. E. A., Khurram, S. A. & Rajpoot, N. M. A novel AI-based score for assessing the prognostic value of intra-epithelial lymphocytes in oral epithelial dysplasia. *Br. J. Cancer* **132**, 168–179 (2025).
39. Dharumalingam, P. *et al.* A Literature Review on Oral Luminoscopy: A Non-invasive Method for Diagnosing Oral Potentially Malignant Disorders. *Cureus* **16**, (2024).
40. Mathur, R., Sharma, R. S., Saini, G., Shukla, S. P. & Jha, A. K. Advancing Oral Cancer Detection and Prevention: Integrating Innovative Screening Tools, Molecular Insights, and Targeted Therapies. *Asian Pac. J. Cancer Biol.* **10**, 507–514 (2025).

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.